Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
03 2021
Historique:
received: 28 09 2020
revised: 01 12 2020
accepted: 18 12 2020
pubmed: 29 12 2020
medline: 15 5 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Important diagnostic and clinical aspects of moderately reduced von Willebrand factor (VWF) levels are still unknown. There is no clear evidence which cutoff value (0.50 vs 0.60 IU/ml) should be used to diagnose "low VWF." Also, the incidence of bleeding after the diagnosis has been made, and risk factors for bleeding are unknown yet. To investigate the incidence of postsurgical bleeding, postpartum hemorrhage (PPH), and traumatic and spontaneous bleeding after low VWF diagnosis, and to develop a risk score to predict future bleeding. We performed a cohort study in patients with historically lowest VWF levels of 0.31 to 0.60 IU/ml. Clinical data of patients were retrospectively collected. We included 439 patients with low VWF. During a follow-up of 6.3 ± 3.7 years, 259 surgical procedures, 81 deliveries, and 109 spontaneous and traumatic bleeding episodes were reported. The incidence of postsurgical bleeding was 2.7%, whereas 10% of deliveries was complicated by PPH. Overall, 65 patients (14.8%) had bleeding requiring treatment, which was not different between patients with historically lowest VWF levels of 0.31-0.50 and 0.51-0.60 IU/ml (p = .154). Age <18 years, abnormal bleeding score at diagnosis, and being referred for bleeding symptoms at the time of diagnosis were independent risk factors for bleeding during follow-up, and therefore included in the risk score. The cutoff value of low VWF diagnosis should be set at 0.60 IU/ml. Furthermore, a risk score is developed to identify individuals with a high risk for bleeding after low VWF diagnosis.

Sections du résumé

BACKGROUND
Important diagnostic and clinical aspects of moderately reduced von Willebrand factor (VWF) levels are still unknown. There is no clear evidence which cutoff value (0.50 vs 0.60 IU/ml) should be used to diagnose "low VWF." Also, the incidence of bleeding after the diagnosis has been made, and risk factors for bleeding are unknown yet.
OBJECTIVES
To investigate the incidence of postsurgical bleeding, postpartum hemorrhage (PPH), and traumatic and spontaneous bleeding after low VWF diagnosis, and to develop a risk score to predict future bleeding.
METHODS
We performed a cohort study in patients with historically lowest VWF levels of 0.31 to 0.60 IU/ml. Clinical data of patients were retrospectively collected.
RESULTS
We included 439 patients with low VWF. During a follow-up of 6.3 ± 3.7 years, 259 surgical procedures, 81 deliveries, and 109 spontaneous and traumatic bleeding episodes were reported. The incidence of postsurgical bleeding was 2.7%, whereas 10% of deliveries was complicated by PPH. Overall, 65 patients (14.8%) had bleeding requiring treatment, which was not different between patients with historically lowest VWF levels of 0.31-0.50 and 0.51-0.60 IU/ml (p = .154). Age <18 years, abnormal bleeding score at diagnosis, and being referred for bleeding symptoms at the time of diagnosis were independent risk factors for bleeding during follow-up, and therefore included in the risk score.
CONCLUSIONS
The cutoff value of low VWF diagnosis should be set at 0.60 IU/ml. Furthermore, a risk score is developed to identify individuals with a high risk for bleeding after low VWF diagnosis.

Identifiants

pubmed: 33370487
doi: 10.1111/jth.15227
pmc: PMC7986755
pii: S1538-7836(22)00702-4
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

719-731

Informations de copyright

© 2021 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

Références

Am J Obstet Gynecol. 2020 Sep;223(3):447.e1-447.e19
pubmed: 32592695
Am Heart J. 2013 Mar;165(3):427-33.e1
pubmed: 23453114
Am J Hematol. 2015 Dec;90(12):1142-8
pubmed: 26375306
Thromb Haemost. 2012 Oct;108(4):683-92
pubmed: 22918553
Int J Gynaecol Obstet. 2006 Oct;95(1):75-87
pubmed: 17106950
Br J Haematol. 2020 Nov;191(3):329-339
pubmed: 32394456
BMC Pregnancy Childbirth. 2015 Feb 21;15:43
pubmed: 25885884
Haemophilia. 2015 Jul;21(4):505-12
pubmed: 25688733
Thromb Haemost. 2011 Nov;106(5):885-92
pubmed: 21947221
Semin Thromb Hemost. 2006 Sep;32(6):605-15
pubmed: 16977570
Transplant Proc. 2006 Apr;38(3):812-4
pubmed: 16647479
Ann Blood. 2018 Jan;3:
pubmed: 30135959
J Thromb Haemost. 2010 Sep;8(9):2063-5
pubmed: 20626619
J Am Coll Cardiol. 2017 Feb 21;69(7):871-898
pubmed: 28081965
BJOG. 2001 Sep;108(9):927-30
pubmed: 11563461
Blood. 2015 May 7;125(19):3006-13
pubmed: 25673639
Blood. 2019 Feb 21;133(8):795-804
pubmed: 30578256
Blood Adv. 2018 Jul 24;2(14):1784-1791
pubmed: 30042144
Blood. 2017 Nov 23;130(21):2344-2353
pubmed: 28916584
Haemophilia. 2008 Mar;14(2):171-232
pubmed: 18315614
Br J Obstet Gynaecol. 1998 Mar;105(3):314-21
pubmed: 9532993
J Thromb Haemost. 2012 Apr;10(4):632-8
pubmed: 22329792
J Thromb Haemost. 2010 Jan;8(1):213-6
pubmed: 19874468
Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1279-84
pubmed: 7726270
Haemophilia. 2020 May;26(3):503-512
pubmed: 32159272
Blood. 2003 Mar 15;101(6):2089-93
pubmed: 12411289
Haemophilia. 2014 Nov;20(6):831-5
pubmed: 25196510
Blood. 2008 Apr 1;111(7):3531-9
pubmed: 18230755
J Thromb Haemost. 2006 Oct;4(10):2164-9
pubmed: 16999850
Hematology Am Soc Hematol Educ Program. 2009;:106-12
pubmed: 20008188
Otolaryngol Head Neck Surg. 2000 Sep;123(3):229-35
pubmed: 10964296
Blood. 1987 Feb;69(2):454-9
pubmed: 3492222
Blood. 2014 Jun 26;123(26):4037-44
pubmed: 24786773
BMJ Open. 2019 Jul 30;9(7):e028576
pubmed: 31366651
Int J Lab Hematol. 2017 May;39 Suppl 1:61-68
pubmed: 28447419
Br J Haematol. 2014 Nov;167(4):453-65
pubmed: 25113304
Clin Chem. 2013 Apr;59(4):684-91
pubmed: 23340442
Blood. 2016 May 19;127(20):2481-8
pubmed: 26862110
Blood Adv. 2020 Jul 14;4(13):3191-3199
pubmed: 32663299
N Engl J Med. 2016 Nov 24;375(21):2067-2080
pubmed: 27959741
J Cardiothorac Vasc Anesth. 2018 Aug;32(4):1618-1624
pubmed: 29338997

Auteurs

Ferdows Atiq (F)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Esmee Wuijster (E)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Moniek P M de Maat (MPM)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Marieke J H A Kruip (MJHA)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Marjon H Cnossen (MH)

Department of Pediatric Hematology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Frank W G Leebeek (FWG)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH